Strata Oncology Inc. in Ann Arbor, a precision oncology company advancing molecular indications for cancer therapies, today announced the completion of a $90 million Series C financing.
The investment brings the firm’s total financing to more than $130 million since its founding. The proceeds will be used to accelerate the development of Strata Oncology’s personalized minimal residual disease (MRD) assay for early-stage cancers and advance its pipeline of novel RNA-based treatment selection tests for solid tumors.
Wellington Management led the financing and was joined by other new investors including Cormorant Asset Management, Monashee Investment Management, and Highside Capital Management.
Strata Oncology’s existing investors, including Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital, and Renaissance Venture Capital Fund also participated in the financing. J.P. Morgan served as sole placement agent to Strata Oncology on the financing.
“We are grateful to our new and existing investors for their commitment to our bold mission of delivering the best possible treatment for each patient, as early as possible,” says Dan Rhodes, co-founder and CEO of Strata Oncology. “This financing will enable us to increase our investment in our platform, programs, and team, as we combine highly sensitive MRD testing with DNA and quantitative RNA-informed treatment selection testing.”
The financing supports Strata Oncology’s efforts to expand its comprehensive genomic and transcriptomic profiling platform to deliver a portfolio of industry-leading treatment selection tests for solid tumors.
The company’s platform, which integrates comprehensive genomic profiling and highly quantitative RNA expression profiling, enables comprehensive molecular insights from a single, minute tumor tissue specimen. In a recent study shared at the 2021 American Society of Clinical Oncology Annual Meeting, Strata Oncology demonstrated the potential of its platform, identifying a new multifactorial biomarker that can predict immune checkpoint inhibitor benefit.
Strata Oncology combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer. StrataNGS is a comprehensive genomic profiling test that features the lowest tumor tissue requirements in the industry so that more patients can get the results and treatments they need.
For more information visit strataoncology.com.